Lupin Ltd Share Price – NSE  / BSE

Pharmaceuticals, Mid Cap

The EIR was issued following an inspection of the facility from 08 September 2025 to 16 September 2025.

Nilesh Gupta, managing director, Lupin, said: ?We are pleased to have received the EIR from the U.S. FDA with a VAI classification for our Nagpur injectable facility.

We are committed to upholding the highest standards of quality and compliance across our facilities, with continued focus on enhancements to our quality systems and operational excellence.?

Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.

The company had reported a 73.33% surge in consolidated net profit to Rs 1,477.92 crore in Q2 FY26 as against Rs 852.63 crore posted in Q2 FY25. Revenue from operations jumped 24.27% year-on-year to Rs 6,831.43 crore in the quarter ended 30 September 2025.

The counter rose 0.84% to currently trade at Rs 2107.20 on the BSE.

Powered by Capital Market - Live News

Lupin announced that its greenhouse gas (GHG) emissions reduction targets have been officially validated by the Science Based Targets initiative (SBTi). These validations cover all three emission scopes ?V Scope 1, Scope 2, and Scope 3 - aligning with the Paris Agreement to limit global temperature rise to 1.5?XC.

This milestone underscores Lupin??s commitment to sustainability and decisive climate action, positioning the company among a select group that has achieved comprehensive SBTi validation within a year of setting its climate targets.

Key short-term targets:

?h - Reduce absolute Scope 1 and 2 greenhouse gas emissions by 42.0% by FY 2030, with FY 2023 as the base year.

?h - Reduce Scope 3 greenhouse gas emissions by 61.07% by FY 2033, across purchased goods and services, fuel- and energy-related activities, upstream and downstream transportation and distribution, business travel, employee commuting, processing and use of sold products, and franchises, using FY 2024 as the baseline.

These goals are aligned with the 1.5?XC pathway and validated under SBTi??s latest guidelines, thereby positioning Lupin as a key participant in the global effort to combat climate change.

Powered by Capital Market - Live News

Lupin Manufacturing Solutions (LMS), a subsidiary of Lupin, today announced a long-term strategic alliance with PolyPeptide Group AG (PolyPeptide) (SIX: PPGN), a specialized, global CDMO for peptide-based active pharmaceutical ingredients. This collaboration aims to enhance supply chain resilience, improve operational efficiency, and accelerate readiness for the rapidly expanding global peptides market. It also advances next-generation peptide therapeutics, including those for metabolics, supporting the long-term strategic growth of both organizations.

As part of the alliance, both companies will work towards the following: ?h

• Expanding sourcing options and fortifying peptide supply chains to meet rising global demand for peptide APIs, including for metabolic disease therapies. ?h
• Integrating procurement and supply planning ?h
• Ensuring unwavering quality and reliability and delivering superior service globally

This partnership strengthens LMS as a leading CDMO supplier of peptide materials for both innovator and generic markets, while enhancing PolyPeptide??s position as a trusted CDMO partner.

Powered by Capital Market - Live News

Lupin today announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Siponimod Tablets, 0.25 mg, 1 mg and 2 mg. This product would be manufactured at Lupin's Pithampur facility in India.

Siponimod Tablets, 0.25 mg, 1 mg and 2 mg are bioequivalent to Mayzent? Tablets, 0.25 mg, 1 mg and 2 mg of Novartis Pharmaceuticals Corporation, and indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing remitting disease, and active secondary progressive disease, in adults.

Siponimod Tablets (RLD Mayzent?) had estimated annual sales of USD 195 million in the U.S. (IQVIA MAT October 2025).

Powered by Capital Market - Live News